{
  "drug_id": "D009",
  "drug_name": "Immunara",
  "indication": "Immunology-F",
  "modality": "monoclonal antibody",
  "mechanism": "ligand neutralizing antibody",
  "moa_short": "Neutralizes a circulating ligand to reduce pathway activation.",
  "formulation": "vial for infusion",
  "route": "intravenous",
  "regimen": "3 mg/kg Q4W",
  "trial_id": "AMGN-D009-302",
  "phase": "Phase 2",
  "arms": [
    {
      "name": "Immunara 3 mg/kg Q4W",
      "n": 214,
      "dose": "3 mg/kg Q4W"
    },
    {
      "name": "Placebo",
      "n": 206,
      "dose": "matching regimen"
    }
  ],
  "population": "Adults with moderate-to-severe Immunology-F with inadequate response to standard therapy.",
  "key_inclusion": [
    "Confirmed diagnosis per protocol definition",
    "Baseline disease activity above threshold",
    "Stable background therapy for \u22654 weeks"
  ],
  "key_exclusion": [
    "Severe uncontrolled comorbidity (per protocol)",
    "Recent major surgery within 12 weeks",
    "Known hypersensitivity to components"
  ],
  "results": {
    "endpoint_primary": "Change from baseline in Symptom Score at Week 12",
    "endpoint_secondary": "Time to flare through Week 24",
    "primary_effect": "LS mean difference -1.86 (Drug \u2212 Placebo)",
    "primary_pvalue": 0.03667393899271156,
    "primary_ci": "[-2.26, -1.46]",
    "secondary_effect": "Numerically favored active arm; supportive trend",
    "discontinuation_rate_pct": 11.073237895908902
  },
  "safety": {
    "common_ae": [
      [
        "Upper respiratory infection",
        11.758825406095836
      ],
      [
        "Headache",
        8.136592079092894
      ],
      [
        "Rash",
        8.002031521822593
      ],
      [
        "Arthralgia",
        6.346284022652081
      ],
      [
        "Diarrhea",
        6.239640984198547
      ],
      [
        "Nausea",
        6.750802495857167
      ]
    ],
    "serious_ae_rate_pct": 2.982061458112159,
    "discontinuation_ae_rate_pct": 1.090409904135188,
    "warnings": [
      "Monitor for hypersensitivity reactions.",
      "Assess for infection risk in susceptible patients.",
      "Consider hepatic monitoring if clinically indicated."
    ],
    "contraindications": [
      "Known hypersensitivity to active substance or excipients."
    ]
  },
  "monitoring": [
    "Baseline labs per protocol (CBC, CMP)",
    "Periodic assessment of liver enzymes",
    "Clinical monitoring for infections"
  ],
  "version": "v2.8",
  "doc_date": "2025-12-26"
}